Pain Therapeutics


SMi is pleased to present the return of the 18th annual Pain Therapeutics Conference taking place on 21st – 22nd May 2018, London, UK.

We have worked hard to bring together an elite speaker panel to educate and inspire our delegates through the exploration of innovative approaches and novel targets in analgesic medicine.

Attendees will be able to network with industry experts from leading pharma companies, biotech and academics to name but a few. If you want to discover the future of pain therapeutics and be a part of the conversation, visit www.pain-therapeutics.co.uk/EVVNT

2018 Highlights
• Explore the possibilities of DNA-based, disease modifying treatments for painful diabetic neuropathy with ViroMed
• Overcome the challenges of patient recruitment and the placebo response with Novartis
• Learn how AstraZeneca and Eli Lilly are targeting ion channels to reduce pain
• Get involved in round table discussions on chronic pain and depression, the opioid crisis, and alternatives to animal models
• Listen to Centrexion, Amgen, Janssen, Nektar Therapeutics and Grunenthal discuss the current industry outlook

The upcoming Pain Therapeutics conference moves away from well discussed topics such as opioid dependence and animal models and focuses on the most exciting current research, opinions, novel targets and mechanisms and advances in the field of analgesic medicine.

CHAIRS FOR 2018:
• Joseph Stauffer, Chief Medical Officer, Cara Therapeutics
• Randall Stevens, Chief Medical Officer, Centrexion Therapeutics
• Kerrie Brady, Founder and Chief Business Officer, Centrexion Therapeutics

Exhibitors

Amgen, Aptinyx, AstraZeneca, Cara Therapeutics, Centrexion Therapeutics Corp., Danish Headache Centre, Eli Lilly, Flexion Therapeutics, Grunenthal, Innopain, J & JPRD, Lotus Clinical Research, Llc, Mundipharma Research GmbH & Co. KG, Nektar Therapeutics, Novartis Pharmaceuticals, phd pharma design, Prescient Healthcare Group & Viromed

Go to event website